High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal o...
Saved in:
| Published in: | Revue neurologique Vol. 178; no. 10; pp. 1011 - 1030 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
France
Elsevier Masson SAS
01.12.2022
Elsevier Masson |
| Subjects: | |
| ISSN: | 0035-3787 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = −0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits. |
|---|---|
| AbstractList | In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = -0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits. In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = -0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits.In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = -0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits. In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = −0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits. |
| Author | Planche, V. Levy, R. Villain, N. |
| Author_xml | – sequence: 1 givenname: N. surname: Villain fullname: Villain, N. email: nicolas.villain@aphp.fr organization: Assistance Publique – Hôpitaux de Paris, Department of Neurology, Institute of Memory and Alzheimer's Disease, Pitié-Salpêtrière Hospital, Paris, France – sequence: 2 givenname: V. surname: Planche fullname: Planche, V. organization: CNRS, IMN, UMR 5293, University Bordeaux, 33000 Bordeaux, France – sequence: 3 givenname: R. surname: Levy fullname: Levy, R. organization: Assistance Publique – Hôpitaux de Paris, Department of Neurology, Institute of Memory and Alzheimer's Disease, Pitié-Salpêtrière Hospital, Paris, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36184326$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-03797247$$DView record in HAL |
| BookMark | eNqFkctuEzEUhmdRRC_wBgh5B0idwZfJTKaLSlFVCFIQLGBtnbGPiSOPHWynKLwMr4rTtCxYwMZHOvr-X_L5zqsTHzxW1QtGG0ZZ93bTeNzF4BpOOW9o11DGT6ozSsWsFv28P63OU9pQyllPxdPqVHRs3grenVW_lvbbulYOIYJXSMBnW8O0d8FqYqdp50NeY4StxUSsJwv3c412wvgqEW0TQsKGfIaYCbsiHzFDDR7cPtlUqjSJeGfxBwmGoDFWgdrfrxMYzHuiIcPl_WJCbVWoUQUfpsI5AmmLKqdn1RMDLuHzh3lRfX13--VmWa8-vf9ws1jVquWC1wYZ7UTHKVNM4VzB4Z2pdhxx1AbGsdNzPWgGptfjjJuhGxAEm3WKI1O9ERfVm2PvGpzcRjtB3MsAVi4XK3nYUdEPPW_7O1bY10d2G8P3HaYsJ5sUOgcewy5J3nM68HYQQ0FfPqC7sfzxT_OjgAJcHQEVQ0oRjVQ2Q7bB5wjWSUblwbDcyKNheTAsaSeL4RJu_wo_9v8ndn2MYTlo8RNlUhaLfW1jubnUwf674Ddhx8aM |
| CitedBy_id | crossref_primary_10_1097_RLU_0000000000004710 crossref_primary_10_2174_0113892037362037250205143911 crossref_primary_10_1016_j_jradnu_2024_04_004 crossref_primary_10_1093_procel_pwae026 crossref_primary_10_1186_s13195_023_01204_x crossref_primary_10_3233_JAD_240688 crossref_primary_10_1016_j_neurol_2022_08_002 crossref_primary_10_1002_alz_12975 crossref_primary_10_7759_cureus_68008 crossref_primary_10_1007_s00415_023_11642_0 crossref_primary_10_1007_s00011_023_01788_y crossref_primary_10_1016_j_arr_2023_102012 crossref_primary_10_1161_STROKEAHA_123_043018 crossref_primary_10_1186_s13195_024_01530_8 crossref_primary_10_3390_bioengineering10020253 crossref_primary_10_3390_medicina59061084 crossref_primary_10_1111_joim_13759 crossref_primary_10_1002_bcp_70021 crossref_primary_10_1007_s40263_024_01067_2 crossref_primary_10_1016_j_lana_2023_100467 crossref_primary_10_1016_j_cccb_2023_100193 crossref_primary_10_3390_ijms26114982 crossref_primary_10_1080_03007995_2023_2260741 crossref_primary_10_1093_brain_awad159 crossref_primary_10_1080_14712598_2024_2416947 crossref_primary_10_3390_biomedicines12091992 crossref_primary_10_1002_alz_13470 crossref_primary_10_1016_j_tjpad_2025_100094 crossref_primary_10_3233_JAD_230308 crossref_primary_10_1002_alz_13518 crossref_primary_10_3390_ijms26010241 crossref_primary_10_1016_j_expneurol_2024_115002 crossref_primary_10_1002_alz_14134 crossref_primary_10_3389_fimmu_2022_1082036 crossref_primary_10_1007_s12035_025_05020_2 crossref_primary_10_1007_s40120_023_00466_9 crossref_primary_10_1097_WCO_0000000000001252 crossref_primary_10_1186_s13195_024_01595_5 crossref_primary_10_3233_JAD_230559 crossref_primary_10_33549_physiolres_935447 crossref_primary_10_1016_j_arr_2023_101959 crossref_primary_10_1007_s10072_023_07194_w crossref_primary_10_1631_jzus_B2400016 crossref_primary_10_3233_JAD_221026 crossref_primary_10_1016_j_cell_2023_08_021 crossref_primary_10_1007_s40267_024_01108_2 crossref_primary_10_1080_14712598_2025_2463963 crossref_primary_10_3390_ijms26157175 crossref_primary_10_1111_ejn_16500 crossref_primary_10_3389_fphar_2024_1405423 crossref_primary_10_1002_trc2_12454 crossref_primary_10_1016_j_arr_2023_102003 crossref_primary_10_1021_acschemneuro_4c00392 crossref_primary_10_1002_alz_13092 crossref_primary_10_1371_journal_pmed_1004568 crossref_primary_10_3390_ijms241512411 crossref_primary_10_1016_j_cccb_2022_100156 |
| Cites_doi | 10.1002/alz.057492 10.1038/s41582-019-0281-2 10.1126/science.abi6401 10.1056/NEJMoa1304839 10.1002/sim.5403 10.1001/jamaneurol.2022.0315 10.1001/jamaneurol.2021.5205 10.1016/j.trci.2016.06.002 10.1016/j.jalz.2011.03.005 10.1056/NEJMc2111960 10.3233/JAD-180675 10.14283/jpad.2021.26 10.1016/S0197-4580(97)00047-X 10.1016/j.biopsych.2017.08.010 10.1038/376775a0 10.1016/j.jval.2016.10.011 10.1056/NEJMoa1705971 10.1186/s13195-019-0559-z 10.1001/jamaneurol.2021.3404 10.1016/j.jalz.2011.05.2351 10.1056/NEJMoa2100708 10.1186/s13195-017-0318-y 10.1136/jnnp-2015-312383 10.14283/jpad.2021.45 10.1016/j.jalz.2018.02.018 10.1002/sim.4780080407 10.1038/s41591-021-01369-8 10.1002/alz.12379 10.14283/jpad.2021.41 10.1111/jnc.13632 10.1212/WNL.0b013e3181c67808 10.1212/WNL.0000000000012451 10.1038/nature19323 10.1212/WNL.0000000000001877 10.1016/j.mayocp.2016.02.012 10.3233/ADR-210307 10.1001/jamainternmed.2021.4607 10.14283/jpad.2022.34 10.1016/j.trci.2019.06.005 10.1212/WNL.0000000000012022 10.1038/s41582-021-00557-x 10.1016/j.jalz.2011.03.008 10.14283/jpad.2020.68 10.14283/jpad.2022.21 10.1007/s12603-021-1657-8 10.1001/jamaneurol.2021.3126 10.1016/S1474-4422(21)00066-1 10.1002/alz.12615 10.1038/ng1718 10.1001/jamainternmed.2021.4604 10.1038/375754a0 10.1111/jgs.17462 10.1136/jnnp-2011-300881 10.1126/science.1566067 10.1001/jama.2021.14861 10.1093/hmg/5.7.985 10.1056/NEJMp2110468 10.15252/emmm.201606210 10.1007/s40120-021-00273-0 10.1038/ng1292-255 10.1093/aje/kwac063 10.1016/j.jalz.2014.07.003 10.1007/s00401-022-02433-4 10.1016/j.phrs.2021.105754 10.1038/s41573-022-00391-w 10.1016/S2215-0366(21)00197-8 10.1038/353844a0 10.1126/science.7638621 10.1038/349704a0 10.1016/j.eururo.2018.03.006 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) Copyright © 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2022 The Author(s) – notice: Copyright © 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES |
| DOI | 10.1016/j.neurol.2022.06.012 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | 1030 |
| ExternalDocumentID | oai:HAL:hal-03797247v1 36184326 10_1016_j_neurol_2022_06_012 S003537872200738X |
| Genre | Meta-Analysis Journal Article Review |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- --M 08J 08T 0R~ 123 4.4 457 53G 5RE 6I. AACTN AADPK AAEDT AAEDW AAFTH AAFWJ AAIAV AAKOC AALRI AAOAW AAXLA AAXUO ABFNM ABIVO ABLVK ABMAC ABMZM ABYKQ ACDAQ ACRLP ADBBV AEBSH AENEX AFKWA AFTJW AFXIZ AGUBO AIEXJ AIKHN AITUG AJBFU ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BNPGV CS3 DU5 EBS EFJIC EFLBG EJD F5P FDB FIRID FYGXN HZ~ KOM O9- P2P ROL SEM SES SPCBC SSH SSN SSZ T5K ZGI ZXP ~G- AAQFI AATTM AAXKI AAYWO AAYXX ABJNI ACIEU ACLOT ACVFH ADCNI AEIPS AEUPX AFJKZ AFPUW AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c4232-fe10636201c1ce8ca1ce85c4bbebdfabb6d8d9d1af7db52f969ea3156c2e1c7f3 |
| ISSN | 0035-3787 |
| IngestDate | Tue Oct 14 20:30:00 EDT 2025 Sun Nov 09 14:17:37 EST 2025 Wed Feb 19 02:25:49 EST 2025 Tue Nov 18 22:00:30 EST 2025 Sat Nov 29 07:27:39 EST 2025 Fri Feb 23 02:40:08 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Lecanemab Immunotherapy Gantenerumab Donanemab Aducanumab Amyloid Alzheimer |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4232-fe10636201c1ce8ca1ce85c4bbebdfabb6d8d9d1af7db52f969ea3156c2e1c7f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://hal.sorbonne-universite.fr/hal-03797247 |
| PMID | 36184326 |
| PQID | 2720924939 |
| PQPubID | 23479 |
| PageCount | 20 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03797247v1 proquest_miscellaneous_2720924939 pubmed_primary_36184326 crossref_citationtrail_10_1016_j_neurol_2022_06_012 crossref_primary_10_1016_j_neurol_2022_06_012 elsevier_sciencedirect_doi_10_1016_j_neurol_2022_06_012 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-01 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Revue neurologique |
| PublicationTitleAlternate | Rev Neurol (Paris) |
| PublicationYear | 2022 |
| Publisher | Elsevier Masson SAS Elsevier Masson |
| Publisher_xml | – name: Elsevier Masson SAS – name: Elsevier Masson |
| References | Several private insurers won’t cover Biogen's Alzheimer's drug n.d. https://www.statnews.com/2021/07/14/this-is-unprecedented-several-private-insurers-wont-cover-biogens-alzheimers-drug/.(accessed January 24, 2022). NCA - Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N) - Decision Memo n.d. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305.(accessed April 8, 2022). Honig, Vellas, Woodward, Boada, Bullock, Borrie (bib0830) 2018; 378 Honig, Vellas, Woodward, Boada, Bullock, Borrie (bib0850) 2018; 378 EISAI statement on the centers for medicare and medicaid services’ national coverage determination with coverage with evidence development for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease | News Release: 2022 | Eisai Co., Ltd. n.d. https://www.eisai.com/news/2022/news202226.html.(accessed April 25, 2022). Kim, Prasad (bib1045) 2016; 91 Budd-Haeberlein (bib1215) 2022 Barakos, Purcell, Suhy, Chalkias, Burkett, Grassi (bib0950) 2022; 2 Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA | Biogen n.d. https://investors.biogen.com/news-releases/news-release-details/biogen-submits-final-protocol-aduhelmr-aducanumab-avwa-phase-4 (accessed April 4, 2022). Frisoni, Altomare, Thal, Ribaldi, van der Kant, Ossenkoppele (bib1030) 2022 Wang, Logovinsky, Hendrix, Stanworth, Perdomo, Xu (bib0775) 2016; 87 Filippi, Cecchetti, Spinelli, Vezzulli, Falini, Agosta (bib0955) 2022 Chartier-Harlin, Crawford, Houlden, Warren, Hughes, Fidani (bib0985) 1991; 353 Prentice (bib1040) 1989; 8 Institute for Clinical Economic Review (bib1130) 2021 Roche - [Ad hoc announcement pursuant to Art. 53 LR] Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's disease n.d. https://www.roche.com/media/releases/med-cor-2021-10-08.htm.(accessed January 20, 2022). Methods Update: Value Assessment Framework - ICER n.d. https://icer.org/assessment/value-assessment-framework-2020/#overview.(accessed January 21, 2022). Emanuel (bib1090) 2021; 326 van Dyck (bib0820) 2018; 83 Karran, De Strooper (bib1035) 2016; 139 Wessels, Siemers, Yu, Andersen, Holdridge, Sims (bib0740) 2015; 2 Budd Haeberlein, Aisen, Barkhof, Chalkias, Chen, Cohen (bib0665) 2022; 2022 Duyckaerts, Hauw (bib1020) 1997; 18 Committee for Medicinal Products for Human Use (CHMP) (bib1085) 2018 Sarfaty, Hall, Chan, Virik, Leshno, Gordon (bib1155) 2018; 74 Jutten, Sikkes, Van der Flier, Scheltens, Visser, Tijms (bib0895) 2021; 96 McKhann, Knopman, Chertkow, Hyman, Jack, Kawas (bib0645) 2011; 7 Dunn, Stein, Cavazzoni (bib0865) 2021; 181 Sherrington, Rogaev, Liang, Rogaeva, Levesque, Ikeda (bib0965) 1995; 375 Bruce, Brhlikova, Heath, McGettigan (bib1100) 2019; 16 Jack, Bennett, Blennow, Carrillo, Dunn, Haeberlein (bib1015) 2018; 14 With Aduhelm in limbo, Biogen starts laying off employees n.d. https://www.statnews.com/2022/03/03/with-aduhelm-in-limbo-biogen-starts-laying-off-employees/(accessed April 8, 2022). Greenberg, Bacskai, Hernandez-Guillamon, Pruzin, Sperling, van Veluw (bib0660) 2020; 16 Medicare finalizes its restrictions on new Alzheimer's drug - STAT n.d. https://www.statnews.com/2022/04/07/medicare-final-decision-alzheimers-coverage-biogen-aduhelm/.(accessed April 8, 2022). International Conference on Alzheimer's & Parkinson's Diseases 2011 | ALZFORUM n.d. https://www.alzforum.org/print-series/188576.(accessed January 18, 2022). Shcherbinin, Andersen, Evans, Lo, Lu, Navitsky (bib1075) 2021; 17 Sherrington, Froelich, Sorbi, Campion, Chi, Rogaeva (bib0980) 1996; 5 Dunn, Stein, Temple, Cavazzoni (bib0860) 2021; 385 Klein, Delmar, Voyle, Rehal, Hofmann, Abi-Saab (bib0800) 2019; 11 Costa, Cauda (bib0680) 2022 Sperling, Jack, Black, Frosch, Greenberg, Hyman (bib0630) 2011; 7 Plowey, Bussiere, Rajagovindan, Sebalusky, Hamann, von Hehn (bib0695) 2022 Levy-Lahad, Wijsman, Nemens, Anderson, Goddard, Weber (bib0970) 1995; 269 Karran, De Strooper (bib0855) 2022 Nisticò, Borg (bib0730) 2021; 171 UAE approves use of first, only drug to treat Alzheimer's - News | Khaleej Times n.d. https://www.khaleejtimes.com/news/20211003/uae-approves-use-of-first-and-only-drug-to-treat-alzheimers.(accessed January 24, 2022). Salloway, Farlow, McDade, Clifford, Wang, Llibre-Guerra (bib0795) 2021 Andrews, Desai, Kirson, Zichlin, Ball, Matthews (bib0880) 2019; 5 Sevigny, Chiao, Bussière, Weinreb, Williams, Maier (bib0625) 2016; 537 Blue Cross of Massachusetts will not cover controversial Alzheimer's drug - The Boston Globe n.d. https://www.bostonglobe.com/2021/10/07/business/blue-cross-massachusetts-will-not-cover-controversial-alzheimers-drug/?p1=BGSearch_Advanced_Results (accessed January 24, 2022). Birks, Harvey (bib0890) 2018; 6 Temp, Ly, Doorn, Wagenmakers, Tang, Lutz (bib0675) 2022 INDICATIONS AND USAGE ADUHELM is indicated for the treatment of Alzheimer’ s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, effectiveness data on initiating treatment at 2021. Klunk, Koeppe, Price, Benzinger, Devous, Jagust (bib0685) 2015; 11 Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industy | FDA n.d. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alzheimers-disease-developing-drugs-treatment-guidance-industy.(accessed January 21, 2022). Liu, Schneider, Howard (bib0875) 2021; 8 Scheltens, Vijverberg (bib0930) 2021; 8 Whittington, Campbell, Rind, Fluetsch, Lin, Pearson (bib1120) 2022 Dubois, Villain, Frisoni, Rabinovici, Sabbagh, Cappa (bib1025) 2021; 20 de Souza, Andrade, Borelli, Schilling, Matushita, Portuguez (bib0690) 2021 In Revised Evidence Report, ICER Confirms Judgment That Evidence is Insufficient to Demonstrate Net Health Benefit of Aducanumab for Patients with Alzheimer's Disease - ICER n.d. https://icer.org/news-insights/press-releases/in-revised-evidence-report-icer-confirms-judgment-that-evidence-is-insufficient-to-demonstrate-net-health-benefit-of-aducanumab-for-patients-with-alzheimers-disease/.(accessed January 24, 2022). Vellas, Aisen (bib0910) 2021; 8 Goate, Chartier-Harlin, Mullan, Brown, Crawford, Fidani (bib0990) 1991; 349 Ostrowitzki, Lasser, Dorflinger, Scheltens, Barkhof, Nikolcheva (bib0845) 2017; 9 Klein, Delmar, Kerchner, Hofmann, Abi-Saab, Davis (bib0805) 2021; 8 Cummings, Salloway (bib0920) 2021 Satlin, Wang, Logovinsky, Berry, Swanson, Dhadda (bib0770) 2016; 2 FDA Advisory Committee Throws Cold Water on Aducanumab Filing | ALZFORUM n.d. https://www.alzforum.org/news/community-news/fda-advisory-committee-throws-cold-water-aducanumab-filing.(accessed November 26, 2021). Carter, Desmarais, Bellis, Campion, Clerget-Darpoux, Brice (bib0995) 1992; 2 The “QALY” shouldn’t be used in drug cost-effectiveness reviews - STAT n.d. https://www.statnews.com/2019/02/22/qaly-drug-effectiveness-reviews/.(accessed January 24, 2022). Von Rosenstiel, Haeberlein, Castrillo-Viguera, Chen, O’Gorman, Rajagovindan (bib0900) 2018 Ferrero, Williams, Stella, Leitermann, Mikulskis, O’Gorman (bib0635) 2016; 2 Eisai Turns Over Majority of Aduhelm Rights to Biogen | BioSpace n.d. https://www.biospace.com/article/biogen-and-eisai-modify-deal-on-alzheimer-s-drug-aduhelmbiogen-and-eisai-modify-deal-on-alzheimer-s-drug-aduhelm/.(accessed April 25, 2022). Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease | Biogen n.d. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-reduced-price-aduhelmr-improve-access-patients.(accessed January 19, 2022). Salloway, Cummings (bib0670) 2021; 97 Hunt, Harrison, Covinsky (bib1190) 2021; 69 Alexander, Knopman, Emerson, Ovbiagele, Kryscio, Perlmutter (bib1060) 2021; 385 Japan delays decision on whether to OK new Alzheimer's drug | The Japan Times n.d. https://www.japantimes.co.jp/news/2021/12/23/national/science-health/alzheimers-drug-japan-approval-delay/.(accessed January 24, 2022). Glossary | NICE n.d. https://www.nice.org.uk/Glossary?letter=Q#Quality-adjusted life year.(accessed January 21, 2022). Bussiere, Weinreb, Dunstan, Qian, Arastu, Li (bib0620) 2013; 11 LY3372993 | ALZFORUM n.d. https://www.alzforum.org/therapeutics/ly3372993 (accessed July 17, 2022). Liu, Schmidt, Margolin, Sperling, Koeppe, Mason (bib0640) 2015; 85 (bib1070) 2020 Liu, Howard (bib0870) 2021 Lilly and Roche learn from Biogen's mistakes | Evaluate n.d. https://www.evaluate.com/vantage/articles/news/corporate-strategy/lilly-and-roche-learn-biogens-mistakes (accessed April 5, 2022). Richard, den Brok, van Gool (bib0825) 2021; 17 Schrag, Schott (bib0885) 2012; 83 Ciani, Buyse, Drummond, Rasi, Saad, Taylor (bib1055) 2017; 20 Glymour, Weuve, Dufouil, Mayeda (bib1170) 2022 Brashear, Ketter, Bogert, Di, Salloway, Sperling (bib0655) 2018; 66 Rovelet-Lecrux, Hannequin, Raux, Le Meur, Laquerrière, Vital (bib1000) 2006; 38 Mintun, Lo, Duggan Evans, Wessels, Ardayfio, Andersen (bib0735) 2021; 384 Salloway, Sperling, Fox, Blennow, Klunk, Raskind (bib0940) 2014; 370 Fleming, Powers (bib1050) 2012; 31 EISAI initiates rolling submission to the U.S. FDA for biologics license application of Lecanemab (BAN2401) for early Alzheimer's disease under the accelerated approval pathway | News Release: 2021 | Eisai Co., Ltd. n.d. https://www.eisai.com/news/2021/news202177.html.(accessed November 26, 2021). Rogaev, Sherrington, Rogaeva, Levesque, Ikeda, Liang (bib0975) 1995; 376 Salloway, Sperling, Gilman, Fox, Blennow, Raskind (bib0835) 2009; 73 Liu, Schmidt, Margolin, Sperling, Koeppe, Mason (bib0840) 2015; 85 Herring, Gould, Fillit, Lindgren, Forrestal, Thompson (bib1115) 2021 Albert, DeKosky, Dickson, Dubois, Feldman, Fox (bib0650) 2011; 7 Alzheimer's drugmakers seek accelerated FDA review despite U.S. coverage decision | Reuters n.d. https://www.reuters.com/world/us/eisai-seeking-accelerated-fda-review-alzheimers-drug-after-us-coverage-decision-2022-04-08/.(accessed April 25, 2022). Hardy, Higgins (bib1005) 1992; Cummings (10.1016/j.neurol.2022.06.012_bib0960) 2022; 9 Barakos (10.1016/j.neurol.2022.06.012_bib0950) 2022; 2 10.1016/j.neurol.2022.06.012_bib0615 Wang (10.1016/j.neurol.2022.06.012_bib0775) 2016; 87 Salloway (10.1016/j.neurol.2022.06.012_bib0940) 2014; 370 Sherrington (10.1016/j.neurol.2022.06.012_bib0965) 1995; 375 10.1016/j.neurol.2022.06.012_bib1150 Klunk (10.1016/j.neurol.2022.06.012_bib0685) 2015; 11 Satlin (10.1016/j.neurol.2022.06.012_bib0770) 2016; 2 Sperling (10.1016/j.neurol.2022.06.012_bib0630) 2011; 7 Institute for Clinical Economic Review (10.1016/j.neurol.2022.06.012_bib1130) 2021 Dunn (10.1016/j.neurol.2022.06.012_bib0865) 2021; 181 Filippi (10.1016/j.neurol.2022.06.012_bib0955) 2022 Alexander (10.1016/j.neurol.2022.06.012_bib1060) 2021; 385 10.1016/j.neurol.2022.06.012_bib0725 Sevigny (10.1016/j.neurol.2022.06.012_bib0625) 2016; 537 Selkoe (10.1016/j.neurol.2022.06.012_bib1010) 2016; 8 Sarfaty (10.1016/j.neurol.2022.06.012_bib1155) 2018; 74 Klein (10.1016/j.neurol.2022.06.012_bib0800) 2019; 11 Ross (10.1016/j.neurol.2022.06.012_bib1125) 2022 Sherrington (10.1016/j.neurol.2022.06.012_bib0980) 1996; 5 Ciani (10.1016/j.neurol.2022.06.012_bib1055) 2017; 20 (10.1016/j.neurol.2022.06.012_bib1070) 2020 Prentice (10.1016/j.neurol.2022.06.012_bib1040) 1989; 8 10.1016/j.neurol.2022.06.012_bib1140 Ostrowitzki (10.1016/j.neurol.2022.06.012_bib0845) 2017; 9 Goate (10.1016/j.neurol.2022.06.012_bib0990) 1991; 349 Kim (10.1016/j.neurol.2022.06.012_bib1045) 2016; 91 Gyawali (10.1016/j.neurol.2022.06.012_bib1095) 2021; 181 Jack (10.1016/j.neurol.2022.06.012_bib1015) 2018; 14 Costa (10.1016/j.neurol.2022.06.012_bib0680) 2022 Bruce (10.1016/j.neurol.2022.06.012_bib1100) 2019; 16 van Dyck (10.1016/j.neurol.2022.06.012_bib0820) 2018; 83 10.1016/j.neurol.2022.06.012_bib0715 Andrews (10.1016/j.neurol.2022.06.012_bib0880) 2019; 5 Frisoni (10.1016/j.neurol.2022.06.012_bib1030) 2022 Liu (10.1016/j.neurol.2022.06.012_bib0870) 2021 10.1016/j.neurol.2022.06.012_bib1135 10.1016/j.neurol.2022.06.012_bib0720 Budd Haeberlein (10.1016/j.neurol.2022.06.012_bib0665) 2022; 2022 Yunusa (10.1016/j.neurol.2022.06.012_bib1145) 2021; 5 Honig (10.1016/j.neurol.2022.06.012_bib0830) 2018; 378 10.1016/j.neurol.2022.06.012_bib1080 10.1016/j.neurol.2022.06.012_bib0945 10.1016/j.neurol.2022.06.012_bib0705 Bussiere (10.1016/j.neurol.2022.06.012_bib0620) 2013; 11 Fleming (10.1016/j.neurol.2022.06.012_bib1050) 2012; 31 Whittington (10.1016/j.neurol.2022.06.012_bib1120) 2022 Levy-Lahad (10.1016/j.neurol.2022.06.012_bib0970) 1995; 269 Temp (10.1016/j.neurol.2022.06.012_bib0675) 2022 Salloway (10.1016/j.neurol.2022.06.012_bib0795) 2021 10.1016/j.neurol.2022.06.012_bib0710 Birks (10.1016/j.neurol.2022.06.012_bib0890) 2018; 6 Honig (10.1016/j.neurol.2022.06.012_bib0850) 2018; 378 Karran (10.1016/j.neurol.2022.06.012_bib1035) 2016; 139 10.1016/j.neurol.2022.06.012_bib0790 Brashear (10.1016/j.neurol.2022.06.012_bib0655) 2018; 66 Ferrero (10.1016/j.neurol.2022.06.012_bib0635) 2016; 2 Carter (10.1016/j.neurol.2022.06.012_bib0995) 1992; 2 Chartier-Harlin (10.1016/j.neurol.2022.06.012_bib0985) 1991; 353 Planche (10.1016/j.neurol.2022.06.012_bib1065) 2021; 78 10.1016/j.neurol.2022.06.012_bib0815 Wessels (10.1016/j.neurol.2022.06.012_bib0740) 2015; 2 Committee for Medicinal Products for Human Use (CHMP) (10.1016/j.neurol.2022.06.012_bib1085) 2018 10.1016/j.neurol.2022.06.012_bib0785 10.1016/j.neurol.2022.06.012_bib0700 Mintun (10.1016/j.neurol.2022.06.012_bib0735) 2021; 384 Nisticò (10.1016/j.neurol.2022.06.012_bib0730) 2021; 171 Dubois (10.1016/j.neurol.2022.06.012_bib1025) 2021; 20 Swanson (10.1016/j.neurol.2022.06.012_bib0780) 2021 10.1016/j.neurol.2022.06.012_bib1195 10.1016/j.neurol.2022.06.012_bib1110 Duyckaerts (10.1016/j.neurol.2022.06.012_bib1020) 1997; 18 Plowey (10.1016/j.neurol.2022.06.012_bib0695) 2022 Salloway (10.1016/j.neurol.2022.06.012_bib0670) 2021; 97 de Souza (10.1016/j.neurol.2022.06.012_bib0690) 2021 Cummings (10.1016/j.neurol.2022.06.012_bib0925) 2021; 8 Rogaev (10.1016/j.neurol.2022.06.012_bib0975) 1995; 376 Rovelet-Lecrux (10.1016/j.neurol.2022.06.012_bib1000) 2006; 38 10.1016/j.neurol.2022.06.012_bib1105 10.1016/j.neurol.2022.06.012_bib0810 10.1016/j.neurol.2022.06.012_bib1180 Von Rosenstiel (10.1016/j.neurol.2022.06.012_bib0900) 2018 10.1016/j.neurol.2022.06.012_bib1185 10.1016/j.neurol.2022.06.012_bib1220 Jutten (10.1016/j.neurol.2022.06.012_bib0895) 2021; 96 Vellas (10.1016/j.neurol.2022.06.012_bib0910) 2021; 8 Albert (10.1016/j.neurol.2022.06.012_bib0650) 2011; 7 Salloway (10.1016/j.neurol.2022.06.012_bib0835) 2009; 73 Cummings (10.1016/j.neurol.2022.06.012_bib0920) 2021 Richard (10.1016/j.neurol.2022.06.012_bib0825) 2021; 17 Emanuel (10.1016/j.neurol.2022.06.012_bib1090) 2021; 326 10.1016/j.neurol.2022.06.012_bib0760 Liu (10.1016/j.neurol.2022.06.012_bib0840) 2015; 85 10.1016/j.neurol.2022.06.012_bib1210 Liu (10.1016/j.neurol.2022.06.012_bib0875) 2021; 8 Shcherbinin (10.1016/j.neurol.2022.06.012_bib1075) 2021; 17 Budd-Haeberlein (10.1016/j.neurol.2022.06.012_bib1215) 2022 Liu (10.1016/j.neurol.2022.06.012_bib0640) 2015; 85 10.1016/j.neurol.2022.06.012_bib0765 Klein (10.1016/j.neurol.2022.06.012_bib0805) 2021; 8 Vellas (10.1016/j.neurol.2022.06.012_bib0915) 2021; 25 Hunt (10.1016/j.neurol.2022.06.012_bib1190) 2021; 69 McKhann (10.1016/j.neurol.2022.06.012_bib0645) 2011; 7 10.1016/j.neurol.2022.06.012_bib1175 Greenberg (10.1016/j.neurol.2022.06.012_bib0660) 2020; 16 Scheltens (10.1016/j.neurol.2022.06.012_bib0930) 2021; 8 Hardy (10.1016/j.neurol.2022.06.012_bib1005) 1992; 256 10.1016/j.neurol.2022.06.012_bib0745 Glymour (10.1016/j.neurol.2022.06.012_bib1170) 2022 Karran (10.1016/j.neurol.2022.06.012_bib0855) 2022 Herring (10.1016/j.neurol.2022.06.012_bib1115) 2021 10.1016/j.neurol.2022.06.012_bib1200 10.1016/j.neurol.2022.06.012_bib0750 Schrag (10.1016/j.neurol.2022.06.012_bib0885) 2012; 83 Selkoe (10.1016/j.neurol.2022.06.012_bib0905) 2021; 373 10.1016/j.neurol.2022.06.012_bib0755 10.1016/j.neurol.2022.06.012_bib1205 10.1016/j.neurol.2022.06.012_bib1160 Dunn (10.1016/j.neurol.2022.06.012_bib0860) 2021; 385 Manly (10.1016/j.neurol.2022.06.012_bib1165) 2021; 78 |
| References_xml | – volume: 5 start-page: 354 year: 2019 end-page: 363 ident: bib0880 article-title: Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials publication-title: Alzheimers Dement Transl Res Clin Interv – volume: 16 start-page: 1 year: 2019 end-page: 30 ident: bib1100 article-title: The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011–2018 publication-title: PLoS Med – volume: 2 start-page: 211 year: 2022 end-page: 220 ident: bib0950 article-title: Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy publication-title: J Prev Alzheimer's Dis – volume: 353 start-page: 844 year: 1991 end-page: 846 ident: bib0985 article-title: Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene publication-title: Nat – reference: With Aduhelm in limbo, Biogen starts laying off employees n.d. https://www.statnews.com/2022/03/03/with-aduhelm-in-limbo-biogen-starts-laying-off-employees/(accessed April 8, 2022). – start-page: S168 year: 2018 end-page: S169 ident: bib0900 publication-title: Aducanumab 48-month analyses from prime a phase 1b study in patients with early Alzheimer's disease – volume: 85 start-page: 692 year: 2015 end-page: 700 ident: bib0840 article-title: Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials publication-title: Neurology – volume: 376 start-page: 775 year: 1995 end-page: 778 ident: bib0975 article-title: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene publication-title: Nature – volume: 25 start-page: 821 year: 2021 end-page: 823 ident: bib0915 article-title: Editorial: the geriatrician, the primary care physician, aducanumab and the FDA decision: from frustration to new hope publication-title: J Nutr Health Aging – volume: 385 start-page: 856 year: 2021 end-page: 857 ident: bib0860 article-title: An appropriate use of accelerated approval – aducanumab for Alzheimer's disease publication-title: N Engl J Med – volume: 349 start-page: 704 year: 1991 end-page: 706 ident: bib0990 article-title: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease publication-title: Nature – volume: 2 start-page: 227 year: 2015 end-page: 241 ident: bib0740 article-title: A combined measure of cognition and function for clinical trials: the integrated Alzheimer's Disease Rating Scale (iADRS) publication-title: J Prev Alzheimer's Dis – reference: Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease | Biogen n.d. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-reduced-price-aduhelmr-improve-access-patients.(accessed January 19, 2022). – volume: 8 start-page: 1013 year: 2021 end-page: 1016 ident: bib0875 article-title: The need to show minimum clinically important differences in Alzheimer's disease trials publication-title: Lancet Psychiatry – reference: EISAI initiates rolling submission to the U.S. FDA for biologics license application of Lecanemab (BAN2401) for early Alzheimer's disease under the accelerated approval pathway | News Release: 2021 | Eisai Co., Ltd. n.d. https://www.eisai.com/news/2021/news202177.html.(accessed November 26, 2021). – reference: Aduhelm: Pending EC decision | European Medicines Agency n.d. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/aduhelm (accessed January 18, 2022). – reference: Blue Cross of Massachusetts will not cover controversial Alzheimer's drug - The Boston Globe n.d. https://www.bostonglobe.com/2021/10/07/business/blue-cross-massachusetts-will-not-cover-controversial-alzheimers-drug/?p1=BGSearch_Advanced_Results (accessed January 24, 2022). – year: 2021 ident: bib0795 article-title: A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease publication-title: Nat Med – volume: 256 start-page: 184 year: 1992 end-page: 185 ident: bib1005 article-title: Alzheimer's disease: the amyloid cascade hypothesis publication-title: Science – volume: 83 start-page: 311 year: 2018 end-page: 319 ident: bib0820 article-title: Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and promise publication-title: Biol Psychiatry – volume: 139 start-page: 237 year: 2016 end-page: 252 ident: bib1035 article-title: The amyloid cascade hypothesis: are we poised for success or failure? publication-title: J Neurochem – reference: FDA Grants Accelerated Approval for Alzheimer's Drug | FDA n.d. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug (accessed November 26, 2021). – reference: Lilly and Roche learn from Biogen's mistakes | Evaluate n.d. https://www.evaluate.com/vantage/articles/news/corporate-strategy/lilly-and-roche-learn-biogens-mistakes (accessed April 5, 2022). – volume: 38 start-page: 24 year: 2006 end-page: 26 ident: bib1000 article-title: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy publication-title: Nat Genet – volume: 11 start-page: 1e4 year: 2015 end-page: 15e4 ident: bib0685 article-title: The Centiloid project: standardizing quantitative amyloid plaque estimation by PET publication-title: Alzheimers Dement – reference: News | Alzheimer's Association n.d. https://www.alz.org/news/2021/next-steps-for-new-alzheimers-treatment.(accessed January 24, 2022). – volume: 8 start-page: 398 year: 2021 end-page: 410 ident: bib0925 article-title: Aducanumab: appropriate use recommendations publication-title: J Prev Alzheimer's Dis – year: 2021 ident: bib1130 article-title: Aducanumab for Alzheimer's disease: effectiveness and value – reference: Alzheimer's drugmakers seek accelerated FDA review despite U.S. coverage decision | Reuters n.d. https://www.reuters.com/world/us/eisai-seeking-accelerated-fda-review-alzheimers-drug-after-us-coverage-decision-2022-04-08/.(accessed April 25, 2022). – volume: 2 start-page: 169 year: 2016 end-page: 176 ident: bib0635 article-title: First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease publication-title: Alzheimer Dement Transl Res Clin Interv – reference: UAE approves use of first, only drug to treat Alzheimer's - News | Khaleej Times n.d. https://www.khaleejtimes.com/news/20211003/uae-approves-use-of-first-and-only-drug-to-treat-alzheimers.(accessed January 24, 2022). – reference: Eli Lilly pushes back timeline for Alzheimer's drug application | Reuters n.d. https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-profit-falls-18-higher-costs-2022-02-03/(accessed April 5, 2022). – start-page: 13 year: 2021 end-page: 15 ident: bib0920 article-title: Aducanumab: appropriate use recommendations publication-title: Alzheimers Dement – year: 2022 ident: bib0855 article-title: The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics publication-title: Nat Rev Drug Discov – volume: 385 start-page: 769 year: 2021 end-page: 771 ident: bib1060 article-title: Revisiting FDA approval of aducanumab publication-title: N Engl J Med – reference: Several private insurers won’t cover Biogen's Alzheimer's drug n.d. https://www.statnews.com/2021/07/14/this-is-unprecedented-several-private-insurers-wont-cover-biogens-alzheimers-drug/.(accessed January 24, 2022). – volume: 18 start-page: 362 year: 1997 end-page: 369 ident: bib1020 article-title: Prevalence, incidence and duration of Braak's stages in the general population: can we know? publication-title: Neurobiol Aging – year: 2021 ident: bib1115 article-title: Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer's disease publication-title: Neurol Ther – reference: Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industy | FDA n.d. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alzheimers-disease-developing-drugs-treatment-guidance-industy.(accessed January 21, 2022). – volume: 269 start-page: 970 year: 1995 end-page: 973 ident: bib0970 article-title: A familial Alzheimer's disease locus on chromosome 1 publication-title: Science – volume: 378 start-page: 321 year: 2018 end-page: 330 ident: bib0830 article-title: Trial of solanezumab for mild dementia due to Alzheimer's disease publication-title: N Engl J Med – reference: Glossary | NICE n.d. https://www.nice.org.uk/Glossary?letter=Q#Quality-adjusted life year.(accessed January 21, 2022). – reference: INDICATIONS AND USAGE ADUHELM is indicated for the treatment of Alzheimer’ s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, effectiveness data on initiating treatment at 2021. – volume: 2 start-page: 1 year: 2016 end-page: 12 ident: bib0770 article-title: Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease publication-title: Alzheimers Dement – volume: 9 start-page: 221 year: 2022 end-page: 230 ident: bib0960 article-title: Aducanumab: appropriate use recommendations update publication-title: J Prev Alzheimer's Dis – volume: 384 start-page: 1691 year: 2021 end-page: 1704 ident: bib0735 article-title: Donanemab in early Alzheimer's disease publication-title: N Engl J Med – year: 2022 ident: bib1125 article-title: Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US publication-title: JAMA Neurol – reference: FDA Advisory Committee Throws Cold Water on Aducanumab Filing | ALZFORUM n.d. https://www.alzforum.org/news/community-news/fda-advisory-committee-throws-cold-water-aducanumab-filing.(accessed November 26, 2021). – reference: Update on the Phase 4 Confirmatory Study of ADUHELM® | Biogen n.d. https://investors.biogen.com/news-releases/news-release-details/update-phase-4-confirmatory-study-aduhelmr.(accessed January 17, 2022). – year: 2021 ident: bib0870 article-title: Can we learn lessons from the FDA's approval of aducanumab? publication-title: Nat Rev Neurol – year: 2022 ident: bib0695 article-title: Alzheimer disease neuropathology in a patient previously treated with aducanumab publication-title: Acta Neuropathol – reference: Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA | Biogen n.d. https://investors.biogen.com/news-releases/news-release-details/biogen-submits-final-protocol-aduhelmr-aducanumab-avwa-phase-4 (accessed April 4, 2022). – reference: EISAI statement on the centers for medicare and medicaid services’ national coverage determination with coverage with evidence development for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease | News Release: 2022 | Eisai Co., Ltd. n.d. https://www.eisai.com/news/2022/news202226.html.(accessed April 25, 2022). – volume: 181 start-page: 1276 year: 2021 end-page: 1278 ident: bib0865 article-title: Approval of aducanumab for Alzheimer disease – the FDA's perspective publication-title: JAMA Intern Med – volume: 73 start-page: 2061 year: 2009 ident: bib0835 article-title: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease publication-title: Neurology – year: 2022 ident: bib1120 article-title: Cost-effectiveness and value-based pricing of aducanumab for patients with early Alzheimer disease – year: 2022 ident: bib0675 article-title: A Bayesian perspective on Biogen's aducanumab trial publication-title: Alzheimers Dement – volume: 171 start-page: 2 year: 2021 end-page: 4 ident: bib0730 article-title: Aducanumab for Alzheimer's disease: a regulatory perspective publication-title: Pharmacol Res – year: 2021 ident: bib0780 article-title: Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open-label extension of the phase 2 proof-of-concept study, BAN2401-G000-201 publication-title: Subjects with early Alzheimer's disease – reference: Eli Lilly Initiates Rolling Submission for Donanemab in Early Alzheimer Disease n.d. https://www.neurologylive.com/view/eli-lilly-initiates-rolling-submission-donanemab-early-alzheimer-disease.(accessed January 17, 2022). – volume: 7 start-page: 263 year: 2011 end-page: 269 ident: bib0645 article-title: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement – reference: Japan delays decision on whether to OK new Alzheimer's drug | The Japan Times n.d. https://www.japantimes.co.jp/news/2021/12/23/national/science-health/alzheimers-drug-japan-approval-delay/.(accessed January 24, 2022). – reference: Roche - [Ad hoc announcement pursuant to Art. 53 LR] Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's disease n.d. https://www.roche.com/media/releases/med-cor-2021-10-08.htm.(accessed January 20, 2022). – volume: 78 start-page: 1307 year: 2021 end-page: 1308 ident: bib1065 article-title: US food and drug administration approval of aducanumab – is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? publication-title: JAMA Neurol – volume: 2022 start-page: 1 year: 2022 end-page: 14 ident: bib0665 article-title: Two randomized phase 3 studies of aducanumab in early Alzheimer's disease publication-title: J Prev Alzheimer's Dis – volume: 373 start-page: 624 year: 2021 end-page: 626 ident: bib0905 article-title: Treatments for Alzheimer's disease emerge publication-title: Science – volume: 537 start-page: 50 year: 2016 end-page: 56 ident: bib0625 article-title: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease publication-title: Nature – volume: 5 start-page: 985 year: 1996 end-page: 988 ident: bib0980 article-title: Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant publication-title: Hum Mol Genet – volume: 8 start-page: 3 year: 2021 end-page: 6 ident: bib0805 article-title: Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab publication-title: J Prev Alzheimer's Dis – volume: 7 start-page: 367 year: 2011 end-page: 385 ident: bib0630 article-title: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup publication-title: Alzheimer Dement J Alzheimer Assoc – volume: 87 start-page: 993 year: 2016 end-page: 999 ident: bib0775 article-title: ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials publication-title: J Neurol Neurosurg Psychiatry – reference: The “QALY” shouldn’t be used in drug cost-effectiveness reviews - STAT n.d. https://www.statnews.com/2019/02/22/qaly-drug-effectiveness-reviews/.(accessed January 24, 2022). – volume: 8 start-page: 595 year: 2016 end-page: 608 ident: bib1010 article-title: The amyloid hypothesis of Alzheimer's disease at 25 years publication-title: EMBO Mol Med – volume: 11 start-page: 2576 year: 2013 ident: bib0620 article-title: Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates publication-title: Neurodegener Dis – volume: 370 start-page: 322 year: 2014 end-page: 333 ident: bib0940 article-title: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease publication-title: N Engl J Med – volume: 2 start-page: 255 year: 1992 end-page: 256 ident: bib0995 article-title: More missense in amyloid gene publication-title: Nat Genet – reference: Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease | Eli Lilly and Company n.d. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy.(accessed November 26, 2021). – volume: 326 start-page: 1367 year: 2021 end-page: 1368 ident: bib1090 article-title: A middle ground for accelerated drug approval-lessons from aducanumab publication-title: JAMA – volume: 91 start-page: 713 year: 2016 end-page: 725 ident: bib1045 article-title: Strength of validation for surrogate end points used in the US food and drug administration's approval of oncology drugs publication-title: Mayo Clin Proc – volume: 6 start-page: CD001190 year: 2018 ident: bib0890 article-title: Donepezil for dementia due to Alzheimer’ s disease publication-title: Cochrane Database Syst Rev – volume: 8 start-page: 238 year: 2021 end-page: 239 ident: bib0910 article-title: New hope for Alzheimer's disease publication-title: J Prev Alzheimer's Dis – year: 2022 ident: bib1215 article-title: Key milestones in Alzheimer's disease – volume: 14 start-page: 535 year: 2018 end-page: 562 ident: bib1015 article-title: NIA-AA research framework: toward a biological definition of Alzheimer's disease publication-title: Alzheimers Dement – volume: 8 start-page: 412 year: 2021 end-page: 413 ident: bib0930 article-title: Commentary: aducanumab: appropriate use recommendations publication-title: J Prev Alzheimer's Dis – reference: Medicare finalizes its restrictions on new Alzheimer's drug - STAT n.d. https://www.statnews.com/2022/04/07/medicare-final-decision-alzheimers-coverage-biogen-aduhelm/.(accessed April 8, 2022). – volume: 16 start-page: 30 year: 2020 end-page: 42 ident: bib0660 article-title: Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways publication-title: Nat Rev Neurol – volume: 378 start-page: 321 year: 2018 end-page: 330 ident: bib0850 article-title: Trial of solanezumab for mild dementia due to Alzheimer's disease publication-title: N Engl J Med – volume: 96 start-page: e2673 year: 2021 end-page: e2684 ident: bib0895 article-title: Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity publication-title: Neurology – reference: In Revised Evidence Report, ICER Confirms Judgment That Evidence is Insufficient to Demonstrate Net Health Benefit of Aducanumab for Patients with Alzheimer's Disease - ICER n.d. https://icer.org/news-insights/press-releases/in-revised-evidence-report-icer-confirms-judgment-that-evidence-is-insufficient-to-demonstrate-net-health-benefit-of-aducanumab-for-patients-with-alzheimers-disease/.(accessed January 24, 2022). – reference: Eisai Turns Over Majority of Aduhelm Rights to Biogen | BioSpace n.d. https://www.biospace.com/article/biogen-and-eisai-modify-deal-on-alzheimer-s-drug-aduhelmbiogen-and-eisai-modify-deal-on-alzheimer-s-drug-aduhelm/.(accessed April 25, 2022). – volume: 20 start-page: 487 year: 2017 end-page: 495 ident: bib1055 article-title: Time to review the role of surrogate end points in health policy: state of the art and the way forward publication-title: Value Health – reference: News | Alzheimer's Association n.d. https://www.alz.org/news/2022/alzheimers-association-disappointed-by-medicare-co.(accessed April 25, 2022). – volume: 181 start-page: 1275 year: 2021 end-page: 1276 ident: bib1095 article-title: Fulfilling the mandate of the US food and drug administration's accelerated approval pathway: the need for reforms publication-title: JAMA Intern Med – reference: NCA - Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N) - Decision Memo n.d. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305.(accessed April 8, 2022). – year: 2021 ident: bib0690 article-title: Amyloid-β PET classification on cognitive aging stages using the centiloid scale publication-title: Mol Imaging Biol – year: 2020 ident: bib1070 article-title: Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document – Aducanumab – reference: LY3372993 | ALZFORUM n.d. https://www.alzforum.org/therapeutics/ly3372993 (accessed July 17, 2022). – volume: 5 start-page: 705 year: 2021 end-page: 713 ident: bib1145 article-title: Comparative value of cholinesterase inhibitors and memantine in persons with moderate-to-severe alzheimer's disease in the United States: a cost-effectiveness analysis publication-title: J Alzheimers Dis Rep – volume: 17 start-page: e057492 year: 2021 ident: bib1075 article-title: TRAILBLAZER-ALZ study: dynamics of amyloid reduction after donanemab treatment publication-title: Alzheimers Dement – year: 2018 ident: bib1085 article-title: Guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease – volume: 66 start-page: 1409 year: 2018 end-page: 1424 ident: bib0655 article-title: Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies publication-title: J Alzheimer's Dis – reference: Methods Update: Value Assessment Framework - ICER n.d. https://icer.org/assessment/value-assessment-framework-2020/#overview.(accessed January 21, 2022). – start-page: Preprint:1 year: 2022 end-page: Preprint:4 ident: bib0680 article-title: A Bayesian reanalysis of the phase III aducanumab (ADU) trial publication-title: J Alzheimer's Dis – volume: 375 start-page: 754 year: 1995 end-page: 760 ident: bib0965 article-title: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease publication-title: Nature – volume: 17 start-page: 1051 year: 2021 end-page: 1055 ident: bib0825 article-title: Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease publication-title: Alzheimer's Dement – volume: 9 start-page: 1 year: 2017 end-page: 15 ident: bib0845 article-title: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease publication-title: Alzheimer's Res Ther – year: 2022 ident: bib0955 article-title: Amyloid-related imaging abnormalities and β-amyloid–targeting antibodies: a systematic review publication-title: JAMA Neurol – reference: International Conference on Alzheimer's & Parkinson's Diseases 2011 | ALZFORUM n.d. https://www.alzforum.org/print-series/188576.(accessed January 18, 2022). – volume: 78 start-page: 1305 year: 2021 end-page: 1306 ident: bib1165 article-title: What the aducanumab approval reveals about Alzheimer disease research publication-title: JAMA Neurol – volume: 31 start-page: 2973 year: 2012 end-page: 2984 ident: bib1050 article-title: Biomarkers and surrogate endpoints in clinical trials publication-title: Stat Med – volume: 83 start-page: 171 year: 2012 end-page: 173 ident: bib0885 article-title: What is the clinically relevant change on the ADAS-Cog? publication-title: J Neurol Neurosurg Psychiatry – volume: 8 start-page: 431 year: 1989 end-page: 440 ident: bib1040 article-title: Surrogate endpoints in clinical trials: definition and operational criteria publication-title: Stat Med – volume: 11 start-page: 1 year: 2019 end-page: 12 ident: bib0800 article-title: Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis publication-title: Alzheimer's Res Ther – volume: 74 start-page: 57 year: 2018 end-page: 62 ident: bib1155 article-title: Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer publication-title: Eur Urol – volume: 7 start-page: 270 year: 2011 end-page: 279 ident: bib0650 article-title: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement – volume: 20 start-page: 484 year: 2021 end-page: 496 ident: bib1025 article-title: Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group publication-title: Lancet Neurol – start-page: 23 year: 2022 ident: bib1030 article-title: The probabilistic model of Alzheimer disease: the amyloid hypothesis revised publication-title: Nat Rev Neurosci – volume: 69 start-page: 3690 year: 2021 end-page: 3692 ident: bib1190 article-title: Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia publication-title: J Am Geriatr Soc – volume: 97 start-page: 543 year: 2021 end-page: 544 ident: bib0670 article-title: Aducanumab, amyloid lowering, and slowing of Alzheimer disease publication-title: Neurology – year: 2022 ident: bib1170 article-title: Aduhelm, the newly approved medication for Alzheimer's disease: what epidemiologists can learn and what epidemiology can offer publication-title: Am J Epidemiol – volume: 85 start-page: 692 year: 2015 end-page: 700 ident: bib0640 article-title: Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials publication-title: Neurology – ident: 10.1016/j.neurol.2022.06.012_bib1105 – ident: 10.1016/j.neurol.2022.06.012_bib0760 – volume: 17 start-page: e057492 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1075 article-title: TRAILBLAZER-ALZ study: dynamics of amyloid reduction after donanemab treatment publication-title: Alzheimers Dement doi: 10.1002/alz.057492 – ident: 10.1016/j.neurol.2022.06.012_bib1195 – start-page: 23 year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib1030 article-title: The probabilistic model of Alzheimer disease: the amyloid hypothesis revised publication-title: Nat Rev Neurosci – volume: 16 start-page: 30 year: 2020 ident: 10.1016/j.neurol.2022.06.012_bib0660 article-title: Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways publication-title: Nat Rev Neurol doi: 10.1038/s41582-019-0281-2 – volume: 373 start-page: 624 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0905 article-title: Treatments for Alzheimer's disease emerge publication-title: Science doi: 10.1126/science.abi6401 – ident: 10.1016/j.neurol.2022.06.012_bib0725 – start-page: Preprint:1 year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0680 article-title: A Bayesian reanalysis of the phase III aducanumab (ADU) trial publication-title: J Alzheimer's Dis – ident: 10.1016/j.neurol.2022.06.012_bib1200 – volume: 370 start-page: 322 year: 2014 ident: 10.1016/j.neurol.2022.06.012_bib0940 article-title: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1304839 – volume: 31 start-page: 2973 year: 2012 ident: 10.1016/j.neurol.2022.06.012_bib1050 article-title: Biomarkers and surrogate endpoints in clinical trials publication-title: Stat Med doi: 10.1002/sim.5403 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib1125 article-title: Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2022.0315 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0955 article-title: Amyloid-related imaging abnormalities and β-amyloid–targeting antibodies: a systematic review publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2021.5205 – volume: 2 start-page: 169 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib0635 article-title: First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease publication-title: Alzheimer Dement Transl Res Clin Interv doi: 10.1016/j.trci.2016.06.002 – volume: 7 start-page: 263 year: 2011 ident: 10.1016/j.neurol.2022.06.012_bib0645 article-title: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.03.005 – volume: 385 start-page: 856 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0860 article-title: An appropriate use of accelerated approval – aducanumab for Alzheimer's disease publication-title: N Engl J Med doi: 10.1056/NEJMc2111960 – ident: 10.1016/j.neurol.2022.06.012_bib0705 – volume: 66 start-page: 1409 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib0655 article-title: Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies publication-title: J Alzheimer's Dis doi: 10.3233/JAD-180675 – ident: 10.1016/j.neurol.2022.06.012_bib1175 – volume: 8 start-page: 238 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0910 article-title: New hope for Alzheimer's disease publication-title: J Prev Alzheimer's Dis doi: 10.14283/jpad.2021.26 – volume: 18 start-page: 362 year: 1997 ident: 10.1016/j.neurol.2022.06.012_bib1020 article-title: Prevalence, incidence and duration of Braak's stages in the general population: can we know? publication-title: Neurobiol Aging doi: 10.1016/S0197-4580(97)00047-X – ident: 10.1016/j.neurol.2022.06.012_bib1205 – volume: 83 start-page: 311 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib0820 article-title: Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and promise publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2017.08.010 – volume: 376 start-page: 775 year: 1995 ident: 10.1016/j.neurol.2022.06.012_bib0975 article-title: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene publication-title: Nature doi: 10.1038/376775a0 – ident: 10.1016/j.neurol.2022.06.012_bib1140 – volume: 20 start-page: 487 year: 2017 ident: 10.1016/j.neurol.2022.06.012_bib1055 article-title: Time to review the role of surrogate end points in health policy: state of the art and the way forward publication-title: Value Health doi: 10.1016/j.jval.2016.10.011 – volume: 11 start-page: 2576 year: 2013 ident: 10.1016/j.neurol.2022.06.012_bib0620 article-title: Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates publication-title: Neurodegener Dis – volume: 378 start-page: 321 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib0850 article-title: Trial of solanezumab for mild dementia due to Alzheimer's disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1705971 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib1120 – volume: 11 start-page: 1 year: 2019 ident: 10.1016/j.neurol.2022.06.012_bib0800 article-title: Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis publication-title: Alzheimer's Res Ther doi: 10.1186/s13195-019-0559-z – ident: 10.1016/j.neurol.2022.06.012_bib0700 – volume: 378 start-page: 321 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib0830 article-title: Trial of solanezumab for mild dementia due to Alzheimer's disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1705971 – volume: 78 start-page: 1305 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1165 article-title: What the aducanumab approval reveals about Alzheimer disease research publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2021.3404 – ident: 10.1016/j.neurol.2022.06.012_bib0785 – volume: 7 start-page: 367 year: 2011 ident: 10.1016/j.neurol.2022.06.012_bib0630 article-title: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup publication-title: Alzheimer Dement J Alzheimer Assoc doi: 10.1016/j.jalz.2011.05.2351 – volume: 384 start-page: 1691 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0735 article-title: Donanemab in early Alzheimer's disease publication-title: N Engl J Med doi: 10.1056/NEJMoa2100708 – volume: 9 start-page: 1 year: 2017 ident: 10.1016/j.neurol.2022.06.012_bib0845 article-title: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease publication-title: Alzheimer's Res Ther doi: 10.1186/s13195-017-0318-y – volume: 87 start-page: 993 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib0775 article-title: ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2015-312383 – ident: 10.1016/j.neurol.2022.06.012_bib0790 – volume: 8 start-page: 412 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0930 article-title: Commentary: aducanumab: appropriate use recommendations publication-title: J Prev Alzheimer's Dis doi: 10.14283/jpad.2021.45 – ident: 10.1016/j.neurol.2022.06.012_bib1080 – volume: 14 start-page: 535 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib1015 article-title: NIA-AA research framework: toward a biological definition of Alzheimer's disease publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2018.02.018 – volume: 8 start-page: 431 year: 1989 ident: 10.1016/j.neurol.2022.06.012_bib1040 article-title: Surrogate endpoints in clinical trials: definition and operational criteria publication-title: Stat Med doi: 10.1002/sim.4780080407 – year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1130 – ident: 10.1016/j.neurol.2022.06.012_bib0615 – ident: 10.1016/j.neurol.2022.06.012_bib0745 – year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0780 article-title: Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open-label extension of the phase 2 proof-of-concept study, BAN2401-G000-201 – year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0795 article-title: A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease publication-title: Nat Med doi: 10.1038/s41591-021-01369-8 – volume: 17 start-page: 1051 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0825 article-title: Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease publication-title: Alzheimer's Dement doi: 10.1002/alz.12379 – ident: 10.1016/j.neurol.2022.06.012_bib0765 – volume: 8 start-page: 398 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0925 article-title: Aducanumab: appropriate use recommendations publication-title: J Prev Alzheimer's Dis doi: 10.14283/jpad.2021.41 – volume: 2022 start-page: 1 year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0665 article-title: Two randomized phase 3 studies of aducanumab in early Alzheimer's disease publication-title: J Prev Alzheimer's Dis – ident: 10.1016/j.neurol.2022.06.012_bib0720 – volume: 2 start-page: 227 year: 2015 ident: 10.1016/j.neurol.2022.06.012_bib0740 article-title: A combined measure of cognition and function for clinical trials: the integrated Alzheimer's Disease Rating Scale (iADRS) publication-title: J Prev Alzheimer's Dis – volume: 139 start-page: 237 issue: Suppl 2 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib1035 article-title: The amyloid cascade hypothesis: are we poised for success or failure? publication-title: J Neurochem doi: 10.1111/jnc.13632 – volume: 16 start-page: 1 year: 2019 ident: 10.1016/j.neurol.2022.06.012_bib1100 article-title: The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011–2018 publication-title: PLoS Med – volume: 73 start-page: 2061 year: 2009 ident: 10.1016/j.neurol.2022.06.012_bib0835 article-title: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease publication-title: Neurology doi: 10.1212/WNL.0b013e3181c67808 – volume: 2 start-page: 1 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib0770 article-title: Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease publication-title: Alzheimers Dement – ident: 10.1016/j.neurol.2022.06.012_bib0815 – volume: 97 start-page: 543 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0670 article-title: Aducanumab, amyloid lowering, and slowing of Alzheimer disease publication-title: Neurology doi: 10.1212/WNL.0000000000012451 – ident: 10.1016/j.neurol.2022.06.012_bib1210 – year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib1085 – volume: 537 start-page: 50 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib0625 article-title: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease publication-title: Nature doi: 10.1038/nature19323 – year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0690 article-title: Amyloid-β PET classification on cognitive aging stages using the centiloid scale publication-title: Mol Imaging Biol – volume: 85 start-page: 692 year: 2015 ident: 10.1016/j.neurol.2022.06.012_bib0840 article-title: Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials publication-title: Neurology doi: 10.1212/WNL.0000000000001877 – volume: 91 start-page: 713 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib1045 article-title: Strength of validation for surrogate end points used in the US food and drug administration's approval of oncology drugs publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2016.02.012 – volume: 5 start-page: 705 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1145 article-title: Comparative value of cholinesterase inhibitors and memantine in persons with moderate-to-severe alzheimer's disease in the United States: a cost-effectiveness analysis publication-title: J Alzheimers Dis Rep doi: 10.3233/ADR-210307 – volume: 181 start-page: 1276 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0865 article-title: Approval of aducanumab for Alzheimer disease – the FDA's perspective publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2021.4607 – volume: 9 start-page: 221 year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0960 article-title: Aducanumab: appropriate use recommendations update publication-title: J Prev Alzheimer's Dis doi: 10.14283/jpad.2022.34 – volume: 5 start-page: 354 year: 2019 ident: 10.1016/j.neurol.2022.06.012_bib0880 article-title: Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials publication-title: Alzheimers Dement Transl Res Clin Interv doi: 10.1016/j.trci.2019.06.005 – start-page: S168 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib0900 – year: 2020 ident: 10.1016/j.neurol.2022.06.012_bib1070 – volume: 96 start-page: e2673 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0895 article-title: Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity publication-title: Neurology doi: 10.1212/WNL.0000000000012022 – start-page: 13 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0920 article-title: Aducanumab: appropriate use recommendations publication-title: Alzheimers Dement – year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0870 article-title: Can we learn lessons from the FDA's approval of aducanumab? publication-title: Nat Rev Neurol doi: 10.1038/s41582-021-00557-x – volume: 7 start-page: 270 year: 2011 ident: 10.1016/j.neurol.2022.06.012_bib0650 article-title: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.03.008 – ident: 10.1016/j.neurol.2022.06.012_bib1185 – volume: 8 start-page: 3 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0805 article-title: Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab publication-title: J Prev Alzheimer's Dis doi: 10.14283/jpad.2020.68 – ident: 10.1016/j.neurol.2022.06.012_bib0750 – volume: 2 start-page: 211 year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0950 article-title: Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy publication-title: J Prev Alzheimer's Dis doi: 10.14283/jpad.2022.21 – volume: 25 start-page: 821 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0915 article-title: Editorial: the geriatrician, the primary care physician, aducanumab and the FDA decision: from frustration to new hope publication-title: J Nutr Health Aging doi: 10.1007/s12603-021-1657-8 – volume: 78 start-page: 1307 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1065 article-title: US food and drug administration approval of aducanumab – is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2021.3126 – volume: 20 start-page: 484 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1025 article-title: Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group publication-title: Lancet Neurol doi: 10.1016/S1474-4422(21)00066-1 – ident: 10.1016/j.neurol.2022.06.012_bib0810 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0675 article-title: A Bayesian perspective on Biogen's aducanumab trial publication-title: Alzheimers Dement doi: 10.1002/alz.12615 – volume: 38 start-page: 24 year: 2006 ident: 10.1016/j.neurol.2022.06.012_bib1000 article-title: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy publication-title: Nat Genet doi: 10.1038/ng1718 – volume: 181 start-page: 1275 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1095 article-title: Fulfilling the mandate of the US food and drug administration's accelerated approval pathway: the need for reforms publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2021.4604 – volume: 375 start-page: 754 year: 1995 ident: 10.1016/j.neurol.2022.06.012_bib0965 article-title: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease publication-title: Nature doi: 10.1038/375754a0 – ident: 10.1016/j.neurol.2022.06.012_bib1150 – volume: 69 start-page: 3690 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1190 article-title: Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia publication-title: J Am Geriatr Soc doi: 10.1111/jgs.17462 – volume: 83 start-page: 171 year: 2012 ident: 10.1016/j.neurol.2022.06.012_bib0885 article-title: What is the clinically relevant change on the ADAS-Cog? publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2011-300881 – volume: 256 start-page: 184 year: 1992 ident: 10.1016/j.neurol.2022.06.012_bib1005 article-title: Alzheimer's disease: the amyloid cascade hypothesis publication-title: Science doi: 10.1126/science.1566067 – volume: 326 start-page: 1367 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1090 article-title: A middle ground for accelerated drug approval-lessons from aducanumab publication-title: JAMA doi: 10.1001/jama.2021.14861 – ident: 10.1016/j.neurol.2022.06.012_bib0715 – ident: 10.1016/j.neurol.2022.06.012_bib0945 – volume: 5 start-page: 985 year: 1996 ident: 10.1016/j.neurol.2022.06.012_bib0980 article-title: Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant publication-title: Hum Mol Genet doi: 10.1093/hmg/5.7.985 – volume: 385 start-page: 769 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1060 article-title: Revisiting FDA approval of aducanumab publication-title: N Engl J Med doi: 10.1056/NEJMp2110468 – volume: 8 start-page: 595 year: 2016 ident: 10.1016/j.neurol.2022.06.012_bib1010 article-title: The amyloid hypothesis of Alzheimer's disease at 25 years publication-title: EMBO Mol Med doi: 10.15252/emmm.201606210 – year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib1115 article-title: Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer's disease publication-title: Neurol Ther doi: 10.1007/s40120-021-00273-0 – volume: 2 start-page: 255 year: 1992 ident: 10.1016/j.neurol.2022.06.012_bib0995 article-title: More missense in amyloid gene publication-title: Nat Genet doi: 10.1038/ng1292-255 – volume: 6 start-page: CD001190 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib0890 article-title: Donepezil for dementia due to Alzheimer’ s disease publication-title: Cochrane Database Syst Rev – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib1170 article-title: Aduhelm, the newly approved medication for Alzheimer's disease: what epidemiologists can learn and what epidemiology can offer publication-title: Am J Epidemiol doi: 10.1093/aje/kwac063 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib1215 – volume: 11 start-page: 1e4 year: 2015 ident: 10.1016/j.neurol.2022.06.012_bib0685 article-title: The Centiloid project: standardizing quantitative amyloid plaque estimation by PET publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2014.07.003 – ident: 10.1016/j.neurol.2022.06.012_bib0710 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0695 article-title: Alzheimer disease neuropathology in a patient previously treated with aducanumab publication-title: Acta Neuropathol doi: 10.1007/s00401-022-02433-4 – volume: 171 start-page: 2 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0730 article-title: Aducanumab for Alzheimer's disease: a regulatory perspective publication-title: Pharmacol Res doi: 10.1016/j.phrs.2021.105754 – ident: 10.1016/j.neurol.2022.06.012_bib1160 – year: 2022 ident: 10.1016/j.neurol.2022.06.012_bib0855 article-title: The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-022-00391-w – ident: 10.1016/j.neurol.2022.06.012_bib1110 – volume: 8 start-page: 1013 year: 2021 ident: 10.1016/j.neurol.2022.06.012_bib0875 article-title: The need to show minimum clinically important differences in Alzheimer's disease trials publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(21)00197-8 – volume: 353 start-page: 844 year: 1991 ident: 10.1016/j.neurol.2022.06.012_bib0985 article-title: Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene publication-title: Nat doi: 10.1038/353844a0 – ident: 10.1016/j.neurol.2022.06.012_bib1135 – volume: 269 start-page: 970 year: 1995 ident: 10.1016/j.neurol.2022.06.012_bib0970 article-title: A familial Alzheimer's disease locus on chromosome 1 publication-title: Science doi: 10.1126/science.7638621 – volume: 85 start-page: 692 year: 2015 ident: 10.1016/j.neurol.2022.06.012_bib0640 article-title: Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials publication-title: Neurology doi: 10.1212/WNL.0000000000001877 – volume: 349 start-page: 704 year: 1991 ident: 10.1016/j.neurol.2022.06.012_bib0990 article-title: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease publication-title: Nature doi: 10.1038/349704a0 – ident: 10.1016/j.neurol.2022.06.012_bib1220 – volume: 74 start-page: 57 year: 2018 ident: 10.1016/j.neurol.2022.06.012_bib1155 article-title: Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2018.03.006 – ident: 10.1016/j.neurol.2022.06.012_bib1180 – ident: 10.1016/j.neurol.2022.06.012_bib0755 |
| SSID | ssj0021703 |
| Score | 2.5337524 |
| SecondaryResourceType | review_article |
| Snippet | In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1011 |
| SubjectTerms | Aducanumab Aged Alzheimer Alzheimer Disease - therapy Amyloid Amyloid beta-Peptides - metabolism Amyloid beta-Peptides - therapeutic use Bayes Theorem Biomarkers Brain - metabolism Donanemab Gantenerumab Human health and pathology Humans Immunotherapy Lecanemab Life Sciences Medicare Psychiatrics and mental health United States |
| Title | High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects |
| URI | https://dx.doi.org/10.1016/j.neurol.2022.06.012 https://www.ncbi.nlm.nih.gov/pubmed/36184326 https://www.proquest.com/docview/2720924939 https://hal.sorbonne-universite.fr/hal-03797247 |
| Volume | 178 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database issn: 0035-3787 databaseCode: AIEXJ dateStart: 20040601 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: false ssIdentifier: ssj0021703 providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFBZpO0pfxq5ddinaGOwhc7AtO7L3FkZHN9oySgd5M7IsU5fUCblR9lP2sr-6c3TxnHah28NeTJBjWfB9PjqSvnMOIW-TgYR5NE08xSTzorAAO8jC0oui2Fd-UIpU6kDhY356moxG6ddO54eLhVmNeV0n19fp9L9CDW0ANobO_gPcTafQAL8BdLgC7HD9K-BRueFJrAZhowEWlSeuYF1eFb0Ko0FszFWlpVi94fj7hap0DRU-d-c1ffAsZ4tegPsFJ2ohPOFyl4i1cBeFCSiwYLzefhcl6j9Rc-o0ofrkfuIpG_2MeQl0aOe87ROfqdVS9XRiTTTERgVuqoBhSSST5KA5McIqS0C0NX2uK7x81t7DCMOWHsTaZRaDqbNTr7PLPGkT0G-ZWbAjwR_tv9mKuOybMffxXTo9q5Fqt9CfXmn4ma53E95Ixm2md3tri-yEPE7BYu4MPx-OvjTL-YD7zCX9xLG7wEytHrw9gD2y67rc5ANtXaAYd9NKR3s85w_IfbtUoUNDsYeko-pHZPfEijEek5_rTKNtptEbTKNVTRumvZtTxzOKPKPBB7rGMuiqoIZldFJSxzLdbFhGkWXvdcMtjlHLsSfk26fD849Hnq334UmUC3ilCsBhHoBLKgOpEinwGssoz1VelCLPB0VSpEUgSl7kcVimg1QJFsQDGapA8pI9Jdv1pFbPCBVFHEuRxwMVF5FkkYBpJhGcwWLdVzISXcIcApm0yfCxJss4c6rHy8xAmCGEGYo_g7BLvOapqUkGc8f_uQM3sw6tcVQz4OsdT74BLjQvwRzwR8PjDNt8xlMeRnwVdMlrR5UMJgU86RO1miznGYorcGOFpV2ybzjU9OVI-HzjnRdk7_dH-pJsL2ZL9Yrck6tFNZ8dkC0-Sg7sx_ALs2Lecg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High-clearance+anti-amyloid+immunotherapies+in+Alzheimer%27s+disease.+Part+1%3A+Meta-analysis+and+review+of+efficacy+and+safety+data%2C+and+medico-economical+aspects&rft.jtitle=Revue+neurologique&rft.au=Villain%2C+N&rft.au=Planche%2C+V&rft.au=Levy%2C+R&rft.date=2022-12-01&rft.issn=0035-3787&rft.volume=178&rft.issue=10&rft.spage=1011&rft_id=info:doi/10.1016%2Fj.neurol.2022.06.012&rft_id=info%3Apmid%2F36184326&rft.externalDocID=36184326 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0035-3787&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0035-3787&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0035-3787&client=summon |